GO
Loading...

Allergan Inc

More

  • Let's make a deal! Global M&A at 7-year high Monday, 30 Jun 2014 | 6:21 AM ET
    Viagra made by Pfizer and Nexiam made by AstraZeneca.

    Investor support for large acquisitions and a desire to trump rivals in consolidating markets have led CEOs to strike big transactions in 2014.

  • NEW YORK, June 30- Investor support for large acquisitions and a desire to trump rivals in consolidating markets have led chief executives to strike big transactions so far in 2014, raising year-to-date global deal volumes to their highest level in seven years.

  • June 27- Pershing Square Capital Management, led by activist investor William Ackman, and Allergan Inc have agreed that calling a special meeting in an effort to elect new board members will not trigger Allergan's so-called "poison pill" measure, settling a lawsuit, the companies said on Friday.

  • Paulson & Co said to amass large stake in Allergan Wednesday, 25 Jun 2014 | 4:53 PM ET
    A doctor draws Allergan Inc. Botox into a syringe before administering it to a patient at the offices of Marcus Facial Plastic Surgery in Redondo Beach, California

    Hedge fund Paulson & Co has amassed a large stake in Allergan and is supportive of a deal between the Botox maker and Valeant Pharmaceuticals.

  • New York, June 25- Hedge fund Paulson& Co has amassed a large stake in Allergan Inc of more than 6 million shares and is supportive of a deal between the Botox maker and Valeant Pharmaceuticals Inc, people familiar with the matter on Wednesday.

  • Early movers: MU, AAPL, DF, MCRS & more Tuesday, 24 Jun 2014 | 7:50 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Insider trading: How rogue is it? Monday, 23 Jun 2014 | 1:41 PM ET

    The authors of the recent study on insider trading that had Wall Street abuzz go a step further on exactly how rogue it is.

  • *$46 bln offer from AbbVie rejected as undervaluing group. LONDON, June 23- Shire flagged the promise of existing and new drugs on Monday as evidence that AbbVie's $46 billion offer undervalued the company, the latest British firm to be targeted by a U.S. group seeking lower taxes.

  • Allergan rejects Valeant's takeover bid...again Monday, 23 Jun 2014 | 10:53 AM ET
    A doctor draws Allergan Inc. Botox into a syringe before administering it to a patient at the offices of Marcus Facial Plastic Surgery in Redondo Beach, California

    Allergan advised investors not to sell their shares to Valeant, which launched a hostile takeover offer for the Botox maker last week.

  • June 23- Allergan Inc on Monday advised investors not to sell their shares to Valeant Pharmaceuticals International which launched a hostile takeover offer for the California- based Botox maker last week, saying it was "grossly inadequate."

  • *$46 bln offer from AbbVie rejected as undervaluing group. LONDON, June 23- Shire flagged the promise of existing and new drugs on Monday as evidence that AbbVie's $46 billion offer undervalued the company, the latest British firm to be targeted by a U.S. group seeking lower taxes.

  • June 23- Allergan Inc on Monday advised investors not to sell their shares to Valeant Pharmaceuticals International which launched a hostile takeover offer for the California- based Botox maker last week, saying it was "grossly inadequate."

  • Aging stinks, so at least make some money from it Monday, 23 Jun 2014 | 8:00 AM ET

    The US population is getting grayer, and while getting old stinks, there are plenty of ways to profit from an aging demographic using ETFs.

  • *$46 bln offer from AbbVie rejected as undervaluing group. LONDON, June 23- Shire is to take a leaf out of AstraZeneca's playbook by giving long-range forecasts for its drugs as it seeks to convince shareholders that AbbVie's $46 billion offer undervalues the business.

  • *$46 bln offer from AbbVie rejected as undervaluing group. LONDON, June 23- Shire is to take a leaf out of AstraZeneca's playbook by giving long-range forecasts for its drugs as it seeks to convince shareholders that AbbVie's $46 billion offer undervalues the business.

  • *Shire rejects AbbVie offer valued at 46.26 pounds a share. LONDON, June 20- British drugmaker Shire has rejected a 27 billion-pound takeover offer from AbbVie, the latest attempt by a U.S. healthcare firm to tap into lower tax rates abroad via an acquisition.

  • LONDON, June 20- British drugmaker Shire has rejected a 27 billion-pound takeover offer from AbbVie, the latest attempt by a U.S. healthcare firm to tap into the London- listed group's low tax rate. Abbvie's takeover offer proposed creating a new U.S.-listed holding company with a UK tax domicile in a so-called "inversion" move.

  • June 18 (Reuters)- Valeant Pharmaceuticals Inc said on Wednesday it began an exchange offer for Botox maker Allergan Inc, taking its hostile $50.8 billion bid directly to shareholders.

  • Midday movers: Nokia, Walgreen, Yelp & More Wednesday, 18 Jun 2014 | 1:00 PM ET
    Traders on the floor of the New York Stock Exchange.

    Some of Wednesday's midday movers:

  • Legalize insider trading? That's ridiculous Wednesday, 18 Jun 2014 | 12:17 PM ET
    Billionaire Galleon Group hedge fund cofounder Raj Rajaratnam departs Manhattan Federal Court during his trial March 23, 2011 in New York City.

    One of the most breathtakingly incompetent ideas I've ever heard is the idea of legalizing all insider trading, says attorney Andrew Stoltmann.